To further confirm that PLT3 exerts its metabolic benefits by targeting adipose tissues, we evaluated the effects of PLT3 treatment in a mouse model with lipodystrophy previously established in our laboratory by adipocyte-selective ablation of murine double minute 2 (MDM2), which exhibits a complete loss of all adipose tissues, accompanied with severe hyperglycemia, hyperinsulinemia, hypercholesterolemia, and fatty liver32. The gene discussed is MDM2; the disease is Hyperinsulinemia.